<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448770</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-cirrhosis-14</org_study_id>
    <nct_id>NCT03448770</nct_id>
  </id_info>
  <brief_title>To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics.</brief_title>
  <official_title>To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients presenting to the emergency department of Institute of Liver and Biliary
      Sciences with known cirrhosis and hepatic encephalopathy with grade II will be included in
      the study. The patient will be randomized into one of the two arms of lactulose or
      polyethylene glycol. The patient on the lactulose arm will be administered 20 to 30 g of
      lactulose orally or by nasogastric tube (3 or more doses within 24 hours ) or if oral intake
      was not possible or inadequate. The Dose will be repeated to ensure 3-4 loose motions per
      day. The Polyethylene Glycol group will get 17 gm of PEG (Polyethylene Glycol) administered
      orally or via nasogastric tube. PEG (Polyethylene Glycol)will be administered in 3-4 doses in
      24 hours to ensure 3-4 loose stools per day.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete reversal of hepatic encephalopathy in both groups.</measure>
    <time_frame>3 days</time_frame>
    <description>Complete reversal is defined as Grade 0 Encephalopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in hepatic encephalopathy by two grades in both groups</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit stay in both groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in both groups</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of encephalopathy changes in Electroencephalography in both groups</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Lactulsoe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactulose : 20-30gm 2-3 doses per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyethlene Glycol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG- 17 gm sachet</intervention_name>
    <description>PEG- 17 gm sachet 3-4 times per day</description>
    <arm_group_label>Polyethlene Glycol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose : 20-30gm</intervention_name>
    <description>Lactulose : 20-30gm</description>
    <arm_group_label>Lactulsoe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented cirrhosis with any underlying etiology

          2. Hepatic encephalopathy of grade II and above

          3. 18 to 65 years of age

        Exclusion Criteria:

          1. Acute change in mental status due to a diagnosis other than hepatic encephalopathy

          2. Patients who have received lactulose as an anticoma measure before enrollment

          3. Patient who have developed encephalopathy post bleed

          4. Patients with gut paralysis

          5. Patients with tense ascites

          6. Patients with altered sensorium due to organic brain disease.

          7. Patients with coexistent psychiatric illness that may hamper the proper assessment of
             hepatic encephalopathy

          8. Hemodynamic instability obviating vasopressors for resuscitation

          9. Acute liver failure defined as severe acute liver injury with encephalopathy and
             international normalized ratio (INR)â‰¥1.5 in a patient without pre-existing liver
             disease

         10. Refusal of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Abhinav Verma, MD</last_name>
    <phone>01146300000</phone>
    <email>abhinav.3183@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Abhinav Verma, MD</last_name>
      <phone>01146300000</phone>
      <email>abhinav.3183@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Abhinav Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

